Skip to main content

Prescription medicine

Magnesium sulfate and potassium chloride and sodium sulfate Brand names: Sutab

Magnesium sulfate and potassium chloride and sodium sulfate (Sutab) is a prescription medicine with an FDA approval on record since 2020. No generic is listed; pharmacies paid $6.74 per Sutab 1.479-0.225-0.188 g tablet in the October 7, 2026 NADAC survey.

  • No generic listed

Check it at the source: the magnesium sulfate and potassium chloride and sodium sulfate FDA label on DailyMed (effective January 31, 2026, Azurity Pharmaceuticals, Inc.); the NDA 213135 record on Drugs@FDA; every magnesium sulfate and potassium chloride and sodium sulfate label on DailyMed.

Highlights of the record

FDA label of January 31, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026

Used for

From the label: indications and usage

SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

Forms and strengths

  • 17.75 g / 2.7 g / 2.25 g

Tablet.

On the market

Earliest approval on file
November 10, 2020 Sutab, Azurity; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals
1 first May 28, 2026; 1 with a marketed status in Drugs@FDA
Labelers listed (NDC)
2 of which 0 under generic applications, 2 under brand applications, repackagers included
Last listed patent
August 4, 2037 Sutab tablets; not a generic launch date

Supply and safety

Pharmacy cost (NADAC)
$6.74 per tablet Sutab 1.479-0.225-0.188 g tablet
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
No recall recorded
FAERS reports
1,582 through July 30, 2026

What is magnesium sulfate and potassium chloride and sodium sulfate used for?

From the label: indications and usage

SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUTAB is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

FDA pharmacologic class: Calculi Dissolution Agent, Osmotic Laxative and Potassium Salt.

Source: FDA drug label (SUTAB), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set c020e973-dccf-4862-999e-17db6209a48a), via openFDA; the full label on DailyMed

What does the patient leaflet for magnesium sulfate and potassium chloride and sodium sulfate say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about SUTAB?

SUTAB and other bowel preparations can cause serious side effects, including: Serious loss of body fluid (dehydration) and changes in body salts (electrolytes) in your blood. These changes can cause: abnormal heartbeats that can cause death. seizures. This can happen even if you have never had a seizure. kidney problems. Your chance of having fluid loss and changes in body salts with SUTAB is higher if you: have heart problems. have kidney problems. take water pills (diuretics) or non-steroidal anti-inflammatory drugs (NSAIDs). Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking SUTAB: vomiting • urinating less often than normal dizziness • headache See “What are the possible side effects of SUTAB?” for more information about side effects.

From the patient leaflet: How should I store SUTAB?

Each SUTAB bottle contains a drying agent (desiccant) canister to help keep the tablets dry (protect from moisture). Store SUTAB at room temperature between 68°F to 77°F (20°C to 25°C). Keep SUTAB and all medicines out of the reach of children.

Source: FDA drug label (SUTAB), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set c020e973-dccf-4862-999e-17db6209a48a), via openFDA; the full label on DailyMed

Is there a generic for magnesium sulfate and potassium chloride and sodium sulfate (Sutab)?

The FDA approved the first generic magnesium sulfate and potassium chloride and sodium sulfate on May 28, 2026. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

The Orange Book lists 4 patents for Sutab tablets, the last expiring on August 4, 2037. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

  • 2020 earliest approval on file
  • 2026 first generic approved
  • 2037 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do pharmacies pay for magnesium sulfate and potassium chloride and sodium sulfate (Sutab)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.74 per Sutab 1.479-0.225-0.188 g tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

  • Sutab 1.479-0.225-0.188 g tablet (brand)
$6.75
$6.54
January 2024October 2026
NADAC per unit, October 7, 2026
Strength and formBrand or genericPharmacy cost30 tablets, or one pen or vial12-month change
Sutab 1.479-0.225-0.188 g tabletBrand$6.74 per tablet$202.18+0.1%

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What does the magnesium sulfate and potassium chloride and sodium sulfate label say about other medicines?

The magnesium sulfate and potassium chloride and sodium sulfate label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine namedSectionWhat the label says
Bisacodyldrug interactionsAvoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking SUTAB [see Warnings and Precautions ( 5.5 )].
Chlorpromazinedrug interactionsAdminister tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.
Digoxindrug interactionsAdminister tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.
Penicillaminedrug interactionsAdminister tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.
Tetracyclinedrug interactionsAdminister tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUTAB to avoid chelation with magnesium.

Check magnesium sulfate and potassium chloride and sodium sulfate against other medicines

Source: FDA drug label (SUTAB), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set c020e973-dccf-4862-999e-17db6209a48a), via openFDA; the full label on DailyMed

What do FAERS reports show for magnesium sulfate and potassium chloride and sodium sulfate?

The FDA Adverse Event Reporting System holds 1,582 reports that list magnesium sulfate and potassium chloride and sodium sulfate among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 41 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

  • Vomiting (named in the label)826
  • Nausea (named in the label)424
  • Drug Ineffective (a use or a product term, not a reaction)140
  • Abdominal Distension (named in the label)94
  • Headache (named in the label)94
  • Abdominal Pain Upper88
  • Pruritus (named in the label)66
  • Wrong Technique In Product Usage Process (a use or a product term, not a reaction)64

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other calculi dissolution agents
the pharmacologic class, with prices and generics
Check an interaction
what two or more labels say about each other